| 8.91 -1.61 (-15.3%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.76  |
1-year : | 22.54 |
| Resists | First : | 15.21 |
Second : | 19.29 |
| Pivot price | 13.18 |
|||
| Supports | First : | 8.59 |
Second : | 7.15 |
| MAs | MA(5) : | 11.17 |
MA(20) : | 13.72 |
| MA(100) : | 18.95 |
MA(250) : | 11.64  |
|
| MACD | MACD : | -1.7 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 9.6 |
| RSI | RSI(14): 22.8 |
|||
| 52-week | High : | 38.25 | Low : | 2.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QNTM ] has closed below the lower bollinger band by 11.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.07 - 10.16 | 10.16 - 10.22 |
| Low: | 8.41 - 8.53 | 8.53 - 8.59 |
| Close: | 8.78 - 8.97 | 8.97 - 9.08 |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Fri, 31 Oct 2025
Quantum BioPharma Ltd. Provides Corporate Update - GlobeNewswire
Thu, 30 Oct 2025
Quantum BioPharma Announces Private Placement to Strengthen Voting Rights and Fund Operations - citybuzz -
Wed, 29 Oct 2025
Quantum BioPharma Ltd. Announces Corporate Updates - Newsfile
Tue, 14 Oct 2025
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group - GlobeNewswire
Tue, 14 Oct 2025
Quantum BioPharma refutes law firms’ securities violation claims - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 30.7 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -11.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.5 % |
| Return on Equity (ttm) | -456.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.79 |
| PEG Ratio | 0 |
| Price to Book value | 8.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|